Andrew D. Seidman, MD, and Miguel Martín, MD, PhD, on Triple-Negative Breast Cancer: Results From the CIBOMA/GEICAM Trial
2018 San Antonio Breast Cancer SymposiumAndrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Miguel Martín, MD, PhD, of the Instituto de Investigacion Sanitaria Gregorio Marañón, discuss phase III study findings on adjuvant capecitabine after standard chemotherapy for people with early triple-negative breast cancer (Abstract GS2-04).
Related Videos
Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life
Laura S. Dominici, MD, of the Dana-Farber Cancer Institute, discusses the lower quality-of-life scores seen after unilateral or bilateral mastectomy compared with breast-conserving...
Hope S. Rugo, MD, on Metastatic Breast Cancer: Treatment for Pretreated Hormone Receptor–Positive Disease
Hope S. Rugo, MD, of the University of California, San Francisco, discusses how treatment with a lower dose of palbociclib (100 mg vs 125 mg) in combination with fulvestrant or tam...
Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care
Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse ...
Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective
Roisin M. Connolly, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses clinical trials during the past year on studies on CDK and PI3K inhibitors in e...
Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: Novel Treatments and Markers
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognost...
